NASDAQ:RVNC - Revance Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Revance Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.59 +0.36 (+2.36 %) (As of 03/29/2020 01:37 AM ET) Add Compare Today's Range$14.28Now: $15.59▼$16.6350-Day Range$12.46MA: $21.43▼$27.8152-Week Range$9.88Now: $15.59▼$27.97Volume1.33 million shsAverage Volume1.02 million shsMarket Capitalization$887.54 millionP/E RatioN/ADividend YieldN/ABeta1.07 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. It is also developing DAXI for forehead lines and lateral canthal lines; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. Revance Therapeutics, Inc. has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVNC Previous Symbol CUSIPN/A CIK1479290 Webhttp://www.revance.com/ Phone510-742-3400Debt Debt-to-Equity Ratio0.11 Current Ratio7.24 Quick Ratio7.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$410,000.00 Price / Sales2,164.73 Cash FlowN/A Price / Cash FlowN/A Book Value$5.00 per share Price / Book3.12Profitability EPS (Most Recent Fiscal Year)($3.67) Net Income$-159,430,000.00 Net MarginsN/A Return on Equity-81.09% Return on Assets-52.00%Miscellaneous Employees170 Outstanding Shares56,930,000Market Cap$887.54 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive RVNC News and Ratings via Email Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RVNC Rates by TradingView Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions How has Revance Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RVNC shares have decreased by 13.2% and is now trading at $15.59. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Revance Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Revance Therapeutics. When is Revance Therapeutics' next earnings date? Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Revance Therapeutics. How were Revance Therapeutics' earnings last quarter? Revance Therapeutics Inc (NASDAQ:RVNC) issued its quarterly earnings data on Monday, February, 24th. The biopharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.97) by $0.02. The biopharmaceutical company earned $0.09 million during the quarter, compared to the consensus estimate of $5.35 million. View Revance Therapeutics' earnings history. What price target have analysts set for RVNC? 8 brokerages have issued 12 month price objectives for Revance Therapeutics' stock. Their forecasts range from $15.00 to $40.00. On average, they anticipate Revance Therapeutics' stock price to reach $28.86 in the next year. This suggests a possible upside of 85.1% from the stock's current price. View analysts' price targets for Revance Therapeutics. What are Wall Street analysts saying about Revance Therapeutics stock? Here are some recent quotes from research analysts about Revance Therapeutics stock: 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (2/21/2020) 2. Mizuho analysts commented, "We estimate a floor valuation of $17/share which includes: additional dilutive financing, Fosun deal, no credit for therapeutics, poor performance in U.S. aesthetics. With credit for therapeutics and fair aesthetic assumptions, we see ~180%+ upside to our base case $37 PT." (4/24/2019) Has Revance Therapeutics been receiving favorable news coverage? News coverage about RVNC stock has been trending very negative on Sunday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Revance Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutRevance Therapeutics. Who are some of Revance Therapeutics' key competitors? Some companies that are related to Revance Therapeutics include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Emergent Biosolutions (EBS), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), HUTCHISON CHINA/S (HCM), PTC Therapeutics (PTCT) and Myokardia (MYOK). What other stocks do shareholders of Revance Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), AbbVie (ABBV), Exelixis (EXEL), Global Blood Therapeutics (GBT), Gilead Sciences (GILD), Viking Therapeutics (VKTX), Intercept Pharmaceuticals (ICPT), Myovant Sciences (MYOV), Amarin (AMRN) and Fate Therapeutics (FATE). Who are Revance Therapeutics' key executives? Revance Therapeutics' management team includes the following people: Mr. L. Daniel Browne, Co-Founder, Pres, CEO & Director (Age 57)Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 44)Dr. Abhay Joshi, Chief Operating Officer (Age 56)Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications What is Revance Therapeutics' stock symbol? Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC." Who are Revance Therapeutics' major shareholders? Revance Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (10.73%), Franklin Resources Inc. (7.94%), Franklin Resources Inc. (6.29%), Capital World Investors (4.72%), Alliancebernstein L.P. (4.32%) and Capital International Investors (2.58%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne and Lauren P Silvernail. View institutional ownership trends for Revance Therapeutics. Which major investors are selling Revance Therapeutics stock? RVNC stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Jacobs Levy Equity Management Inc., Alliancebernstein L.P., Candriam Luxembourg S.C.A., Nisa Investment Advisors LLC, Rice Hall James & Associates LLC, and Citigroup Inc.. View insider buying and selling activity for Revance Therapeutics. Which major investors are buying Revance Therapeutics stock? RVNC stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Perceptive Advisors LLC, Rothschild & Co. Asset Management US Inc., Capital World Investors, Alyeska Investment Group L.P., EAM Global Investors LLC, Sei Investments Co., and Knights of Columbus Asset Advisors LLC. View insider buying and selling activity for Revance Therapeutics. How do I buy shares of Revance Therapeutics? Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Revance Therapeutics' stock price today? One share of RVNC stock can currently be purchased for approximately $15.59. How big of a company is Revance Therapeutics? Revance Therapeutics has a market capitalization of $887.54 million and generates $410,000.00 in revenue each year. The biopharmaceutical company earns $-159,430,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Revance Therapeutics employs 170 workers across the globe. View additional information about Revance Therapeutics. What is Revance Therapeutics' official website? The official website for Revance Therapeutics is http://www.revance.com/. How can I contact Revance Therapeutics? Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected] MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 341 (Vote Outperform)Underperform Votes: 319 (Vote Underperform)Total Votes: 660MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/29/2020 by MarketBeat.com StaffFeatured Article: Are we seeing the beginning of a new bubble?
